Jason Kelly, Ginkgo Bioworks CEO (Adam Glanzman/Bloomberg via Getty Images)

Ex­clu­sive: Pfiz­er, Gink­go sign R&D deal worth up to $331M to de­vel­op RNA drugs

In its lat­est Big Phar­ma deal, Gink­go Bioworks will work with Pfiz­er to de­vel­op new RNA drugs, the Boston-based syn­thet­ic bi­ol­o­gy start­up ex­clu­sive­ly told …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.